Congress quietly exempts premium cigars from FDA oversight
H.R. 2111 — To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations. · Filed by Byron Donalds (R-FL) · 16 cosponsors · Introduced Mar 14, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal tobacco law to exempt 'premium cigars' from FDA regulation by redefining them as non-tobacco products under the Federal Food, Drug, and Cosmetic Act. Premium cigars are defined narrowly as hand-rolled, all-leaf products weighing over 6 pounds per 1,000 units, sold primarily through specialty retailers. The bill cites a 2022 National Academies study finding that premium cigars are used by only 1% of adults, rarely by youth, and pose lower health risks than other tobacco products.
Why we flagged it
The bill's core function is to carve out a specific tobacco product category from federal regulatory oversight, benefiting premium cigar manufacturers and retailers by exempting them from FDA rules that apply to all other tobacco products.
What the text implies
- Exemption may create regulatory arbitrage: manufacturers could reclassify products to meet the narrow 'premium cigar' definition to escape FDA oversight, potentially undermining the intent of the exemption.
- The bill relies on a single 2022 National Academies report and a district court ruling (Judge Mehta's decision) to justify exemption, but does not address whether FDA has appealed or whether the court's reasoning applies to all premium cigars or only a subset.
The full analysis lists 4 implications of this text.
Who stands to gain
premium cigar manufacturers; specialty tobacco retailers; cigar bar operators